Review Article

Multiorgan Drug Action of Levosimendan in Critical Illnesses

Jian Pan,1 Yun-Mei Yang,2 Jian-Yong Zhu,1 and Yuan-Qiang Lu1

1Department of Emergency Medicine, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China
2Department of Geriatric Medicine, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China

Correspondence should be addressed to Yuan-Qiang Lu; luyuanqiang@zju.edu.cn

Received 5 July 2019; Accepted 24 August 2019; Published 19 September 2019

Academic Editor: Nazario Carrabba

Copyright © 2019 Jian Pan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Cardiotonic drugs mainly include digitalis, catecholamines, phosphodiesterase inhibitors, and calcium sensitizers, which have been successively discovered and applied in clinical practice. However, there are only a few new drugs available in this field, and the selection is very limited. Digitalis, catecholamines, and phosphodiesterase inhibitors increase myocardial contractility by increasing intracellular concentrations of cyclic adenosine monophosphate (cAMP) and Ca2+, and this increase in intracellular calcium ion concentration enhances myocardial oxygen consumption and causes arrhythmia. For these reasons, the research focus on positive inotropic agents has shifted from calcium mobilization to calcium sensitization. Intracellular calcium sensitizers are more effective and safer drugs because they do not increase the intracellular concentration of calcium ions. However, only three calcium sensitizers have been fully developed and used in the past three decades. One of these drugs, levosimendan, has multiple molecular targets and exerts its pharmacological effects by not only increasing myocardial contractility, but also enhancing respiratory muscle function and liver and kidney protection, and it is useful for patients with severe sepsis and septic shock. Recently, more than 60 randomized controlled clinical trials of levosimendan have been reported; however, these clinical trials have occasionally shown different findings. This article reviews the research progress of levosimendan in critical illnesses in recent years.

1. Introduction

Preliminary pharmacological studies of levosimendan and its metabolites have shown that levosimendan has an intracellular calcium-sensitizing effect. In addition, its activation of adenosine triphosphate- (ATP-) sensitive potassium channels on vascular smooth muscle membranes produces profound vasodilation. Furthermore, its activation of mitochondrial ATP-sensitive potassium channels exerts a cardioprotective effect and causes selective phosphodiesterase inhibition. These data suggest that the cardiovascular effects of levosimendan are not only merely based on drug-receptor interactions, but also based on its unique and beneficial functions, such as energy metabolism, antioxidative stress, and neurohormonal function, which contrast other types of positive inotropic-vascular drugs. Other studies have shown that levosimendan enhances respiratory muscle function, improves liver and kidney function and subarachnoid hemorrhage, and changes the prognoses of patients with severe sepsis and septic shock (Figure 1).

1.1. Levosimendan: Mechanism of Action. Levosimendan is a calcium sensitizer and exerts its inotropic effect via binding to the Ca++ saturated troponin C of the myocardial thin filament. This action results in stabilization of the Ca-bound conformation of troponin, thereby prolonging the actin-myosin interaction without altering cross-bridge cycling [1]. Although levosimendan inhibits phosphodiesterase III, its inotropic effect seems to depend almost entirely on its calcium-sensitizing properties [2]. Consequently, compared with other inotropic agents, levosimendan does not increase calcium flux into the cell, and this could explain why levosimendan may actually improve diastolic function and does not increase oxygen consumption in the myocardium [3].
supply through coronary vasodilation, so it is recommended for use in patients with acute heart failure and acute coronary syndrome [4–6]. Levosimendan causes vasodilation through its effect on K⁺ channels in high plasma concentrations [7]. Levosimendan also induces vasodilation in other organs, including the myocardium, lungs [8], liver, and kidney. As a result, organ perfusion is improved despite a slight drop in blood pressure in some patients. Whether clinical consequences of levosimendan-related tissue perfusion improvement should be evaluated taking in consideration concurrent improvement in cardiac output. In addition to its inotropic and vasodilator effects, levosimendan has several other important effects, including increase in diaphragm contractility [9, 10], anti-inflammatory effect [11–13], and antiapoptotic effect [14, 15], and affects platelet function [16–18]. In addition, levosimendan stimulated iNOS expression and nitric oxide (NO) production [19, 20]. But these mechanisms are not clear and need further study.

1.2. Levosimendan and Heart Failure. We identified four noteworthy randomized controlled trials of acute decompensated heart failure. These trials mainly covered patients with acute decompensated heart failure and heart failure after myocardial infarction. The severe low-output heart failure study (the LIDO study) compared heart failure patients with less than 35% left ventricular ejection fraction (LVEF) that were given levosimendan treatments with patients given dobutamine treatments. Results of the LIDO study showed that levosimendan had a significant advantage in stabilizing hemodynamics and 180-day mortality of the patients [21]. In evaluating the safety and efficacy of levosimendan in patients with left ventricular failure complicating acute myocardial infarction (RUSSLAN trial), continuous intravenous injection of low-dose levosimendan in patients with heart failure after acute myocardial infarction did not cause adverse reactions, such as hypotension and myocardial ischemia, and significantly reduced the 14-day and 180-day mortality rates compared to patients in the placebo group [22]. SURVIVE trial (levosimendan vs. dobutamine for patients with acute decompensated heart failure) compared responses of patients with acute decompensated heart failure under levosimendan and dobutamine treatments; the results showed no significant difference in 180-day mortality between the two groups. The levosimendan treatment significantly reduced the brain-type natriuretic peptide (BNP) levels in patients after 24 h and continued this beneficial effect for five days. No significant differences in the all-cause mortality, survival time, discharge rate, and 24 h dyspnea were found 31 days post-treatment. Patients in the dobutamine treatment group had significant increases in the incidence of acute heart failure, while patients in the levosimendan treatment group had a higher incidence of adverse reactions, such as atrial fibrillation, hypokalemia, and headache. Nevertheless, the subsequent in-depth analysis on the Finnish subgroup of patients showed a significant difference in mortality between levosimendan and dobutamine treatments. The Finnish patients who underwent the levosimendan treatment had higher beta-blocker usage, and a higher proportion of patients with acute myocardial infarction were compared with the Finnish patients who underwent the dobutamine treatment [23].

REVIVE trial (effect of levosimendan on the short-term clinical course of patients with acute decompensated heart failure) compared the treatment responses of decompensated heart failure patients after levosimendan treatment with those of the placebo group, and the results showed that the levosimendan treatment significantly reduced the BNP levels in patients at 6 h, 24 h, and five days posttreatment. Patients in the dobutamine treatment group had higher beta-blocker usage, and a higher proportion of patients with acute myocardial infarction were compared with the placebo group (Table 1).
Table 1: Narrative summaries of main controlled trials of levosimendan in acute heart failure.

| Study | Eligible patients | Control | Outcome |
|-------|-------------------|---------|---------|
| LIDO  | Low-output heart failure (EF < 0.35, CO < 0.25, and PCWP > 15 mmHg) | Levosimendan vs. dobutamine | Hemodynamic performance and mortality at 31 days and 180 days |
| RUSSLAN | Left ventricular failure complicating acute myocardial infarction | Levosimendan vs. placebo | Mortality at 14 days and 180 days |
| SURVIVE | Acute decompensated heart failure (EF < 0.30) | Levosimendan vs. placebo | Mortality at 180 days or affect any secondary clinical outcomes |
| REVIVE I | Acute decompensated heart failure (EF < 0.35) | Levosimendan vs. placebo | Symptomatic benefits |
| REVIVE II | Acute decompensated heart failure (EF < 0.35) | Levosimendan vs. placebo | BNP declined in the levosimendan group |

Importantly, among the four clinical trials, the RUSSLAN trial focused on the treatment of heart failure after acute myocardial infarction. Since then, several studies on levosimendan used for acute coronary syndrome have focused on the evaluation of its safety and efficacy in patients with acute coronary syndrome accompanied by acute heart failure and even cardiogenic shock [22, 26]. Based on these studies, the consensus recommendations are as follows: (1) patients benefit from the levosimendan treatment, which enhances myocardial contractility, stabilizes hemodynamics, improves target organ perfusion, and reduces the hospital readmission rate; (2) compared to other vasoconstrictors, levosimendan has a lower incidence of adverse reactions, such as hypotension, headache, atrial fibrillation, hypokalemia, and tachycardia; (3) the application of levosimendan depends on the heart failure severity, mean arterial pressure, heart rate, and infarct size; and (4) levosimendan can be used in combination with other vasoconstrictors under continuous electrocardiogram (ECG) monitoring.

1.3. Levosimendan and Respiratory Muscle Function. Mechanical ventilation is an important method of life support for patients with critical illnesses. Approximately 40% of patients in intensive care units receive mechanical ventilation, and approximately 25% of the patients encounter difficulties when weaning themselves off mechanical ventilation [27]. The diaphragm, the most important respiratory muscle, is responsible for 60%–80% of breathing work. Diaphragmatic dysfunction caused by sepsis can lead to prolonged mechanical ventilation and increased complications and mortality in patients. Diaphragmatic dysfunction caused by sepsis has been a hot topic in modern critical care medicine and a blind spot in clinical treatment. Active treatment of the primary disease cannot easily improve its clinical outcomes in the short term, and other methods, such as adjusting ventilator parameters or sequentially using invasive and noninvasive therapies, are not ideal [28]. Promotion of diaphragmatic cell regeneration and reduction of apoptosis may be suitable treatments [29].

The diaphragm is a special skeletal muscle that can easily become fatigued. If the body is under stress and the diaphragm has long-term passive contraction, the diaphragm’s metabolism will be high and it will be subjected to intense stress. Thus, the diaphragm will be prone to increasing the hydrolyzed protease expression, structural damage of the muscle fibers, and disuse atrophy [30, 31]. Within three days of mechanical ventilation, disuse atrophy of diaphragmatic fibers occurs in the diaphragm muscle, expressions of caspases 1, 3, 4, 8, and 11 increase due to inflammation, and apoptosis and pyroptosis take place [27, 32, 33].

One study by van Hees et al. showed that intravenous injection of levosimendan enhances the contraction of diaphragmatic muscle fibers by increasing intracellular calcium sensitivity, which provides strong theoretical support for calcium sensitizer treatment in patients with respiratory muscle dysfunction accompanied by chronic obstructive pulmonary disease [9].

A study by Schellekens et al. showed that levosimendan did not affect inflammation of the diaphragm caused by mechanical ventilation and endotoxemia in a mouse model [34]. A follow-up study by Doorduin et al. comparing the intracelular venous injection of levosimendan to placebos in healthy individuals showed that levosimendan significantly enhances the action potential and muscle contractility of the diaphragmatic nerves [10]. In a study by Sterba et al., intravenous injection of levosimendan facilitates the withdrawal of mechanical ventilation in patients with low cardiac output by increasing the LVEF, and oxygenation index; however, it does not improve other indicators, such as respiratory muscle strength or renal function [35]. In a randomized double-blind study by Gordon et al., the median time spent on the ventilator in adult patients with severe sepsis and levosimendan treatment was two days more than that in the control group, with no statistically significant difference [36]. A study of challenges in withdrawing mechanical ventilation which compared the difference between levosimendan and dobutamine treatments in chronic obstructive pulmonary disease patients showed a greater reduction in the pulmonary wedge pressure in the levosimendan treatment group [37]. In general, a few studies have evaluated the effect of levosimendan on the function of respiratory muscles. More basic and clinical experiments should be carried out to investigate whether levosimendan can help patients overcome the challenges associated with withdrawing from mechanical ventilation.

1.4. Levosimendan and Liver and Kidney Functions. Studies on the effects of levosimendan on liver and kidney functions are still very few. Existing reports have shown that levosimendan may have a protective effect on liver and kidney functions, and this effect may be derived from the drug, which acts directly on the liver and kidney and is
unlikely to be related to the improvement of cardiac function. A study by Öktar et al. in a rat model of acute-heart-failure-induced liver failure showed that levosimendan prevents hepatic ischemic-reperfusion injury (IRI) in rats through histological examinations and specific immunohistochemistry [38]. Studies by Onody et al. and Grossini et al. showed that levosimendan prevents hepatic IRI in rats after portal vein embolization, and the specific mechanism may be related to the mitochondrial ATP-sensitive potassium channels. Thus, levosimendan pretreatment in patients with partial liver resection may have a certain protective effect on the liver [39, 40]. A study by Brunner et al. also showed that levosimendan reduces apoptosis in human hepatocytes after ischemia-reperfusion injury [41].

Acute and chronic heart failure combined with renal insufficiency, also known as type 1 and type 2 cardiorenal syndromes, respectively, are very common in clinical practice. General treatments for these syndromes involve using diuretics to reduce cardiac preload, positive inotropics to increase myocardial contractility, and renal replacement therapy. Fedele et al. believed that levosimendan may have potential benefits for patients with acute heart and kidney syndromes accompanied by hypotension. However, its specific mechanism still needs further study for validation [42]. The European Heart Association recommends using levosimendan in patients with advanced heart failure or heart failure accompanied by renal insufficiency to improve the renal outcomes by dilating renal blood vessels and increasing renal blood perfusion and to improve the prognosis of patients [43, 44]. However, no significant effect of levosimendan on renal function was reported in either of the two randomized controlled trials of REVIVE I and II [24]. Several animal studies have shown that levosimendan improves cardiac function as well as reduces the pressure of renal arteries, ultimately increasing the renal blood flow [45–47]. Some studies have shown that levosimendan improves renal function in patients with congestive heart failure [48], especially heart failure patients with low ejection fraction, which may be related to the selective dilation of renal arteries and veins and increased renal perfusion [49]. Levosimendan also increases renal blood flow and improves the glomerular filtration rate in patients after cardiac surgery [50–52]. Limited studies of levosimendan effects on septic shock have shown that levosimendan increases creatinine clearance in plasma [53]. The Levosimendan for the Prevention of Acute Organ Dysfunction in Sepsis (LeoPARDS) trial showed that the incidence of new acute kidney event, new requirement for renal replacement therapy, and sustained renal failure (stage 2 or 3 acute kidney injury) at day 28 and the duration of renal replacement therapy did not differ significantly between the levosimendan group and the control group. The duration of renal replacement therapy was two days shorter in the levosimendan group than in the control group, although the difference was not statistically significant [36].

1.5. Levosimendan and Severe Sepsis and Septic Shock. Sepsis has been increasingly recognized as causing organ damage due to a microbial invasion of the body, leading to systemic inflammatory dysfunction and immune response. An increasing number of studies have shown that lung, kidney, heart, and skeletal muscles may become damaged by sepsis. Use of levosimendan in severe sepsis and septic shock is a hot research topic in patients with critical illnesses. More than 10 randomized controlled trials of this type are available, trials with positive results accounting for the majority [54–61] and one trial showing neutral results [36]. A 2016 study by Gordon et al. in The New England Journal of Medicine, with the largest number of tested subjects to date, demonstrated that levosimendan significantly reduces mortality in patients relative to normal controls. Although this study has somewhat neutral results, researchers still have great hope for levosimendan in the treatment of sepsis. In a previous study, levosimendan did not improve the function of vital organs compared to the standard controls and it required a larger dose of norepinephrine to maintain mean arterial pressure and resulted in a higher incidence of supraventricular tachycardia. However, this study has some significant data imbalances and design insufficiencies [62]. For example, the inclusion rate of heart failure patients after myocardial infarction in this study is low. The second important shortcoming of this study is the absence of a control group; the only comparison made is between the standard group and the same group added with the levosimendan treatment.

Comparison of some recent meta-analyses has shown little difference among the selected randomized controlled studies. However, their conclusions are completely different. In 2015, a meta-analysis of seven large randomized controlled trials by Zangrillo et al. showed that patients with severe sepsis and septic shock that were given levosimendan treatment had significantly lower mortality than those taking dobutamine [63]. However, subsequent meta-analyses have shown negative results. For example, Bhattacharjee et al. selected seven randomized controlled trials and concluded that levosimendan treatment had no beneficial effects compared to dobutamine treatment [64]. In 2018, a meta-analysis of 10 recent randomized controlled trials conducted by Chang et al. showed that the levosimendan group had no beneficial results compared to the dobutamine or control groups. The sequential analysis of the total number of cases (TSA) showed that the number of cases involved was too small to obtain reliable findings (Figure 2) [65]. These randomized controlled trials had different population inclusion criteria, drug concentrations for treatment, treatment regimens for controls, and study endpoints. As a result, the homogeneity of these meta-analyses was not strong. Therefore, the lack of consistency in the results of these different meta-analyses is reasonable.

1.6. Levosimendan and Cardiogenic Shock. Cardiogenic shock complicates approximately 5% of myocardial infarctions with a high hospital mortality rate approaching 27%–51% [66–70]. In cardiogenic shock complicating myocardial infarction, early revascularization of the occluded vessel by percutaneous coronary intervention is the first-line strategy. A supportive approach is to give
mechanical support, such as intra-aortic balloon pump (IABP), ventricular assist device (VAD), and extracorporeal membrane oxygenation (ECMO). We often choose dobutamine as the inotropic agent for the support of cardiogenic shock. Because levosimendan can cause hypotension in some patients during continuous injection, there are some worries about the use of levosimendan in patients with cardiogenic shock. Recent studies on the use of levosimendan in cardiogenic shock have shown that levosimendan is associated with the improvement in hemodynamics and cardiac function, but with no significant improvement in survival [71].

A retrospective cohort study about patients hospitalized in ICU undergoing venoarterial (VA) ECMO was conducted in a French university hospital from 2010 to 2017; results suggested that levosimendan can exert a beneficial effect on VA-ECMO weaning in ICU patients [61]. And it may reduce the need for high-dose inotropes in another study [72]. There is no more evidence on levosimendan therapy for acute viral myocarditis [73, 74] and postpartum cardiomyopathy [75, 76] in humans to date.

2. Conclusion and Future Perspective

To date, more than 60 clinical trials on levosimendan have been reported, including more than ten thousand patients. However, the results of those trials have been inconsistent, which creates great confusion for physicians trying to select positive inotropic agents for patients with acute and chronic heart failure or severely infected patients with myocardial stunning. Despite the development of this medicine and the completed clinical trials in this field, the exact role of levosimendan in respiratory muscle, liver, and kidney function, and in the neuroendocrine aspect, still remains unclear (Table 2). This review article summarizes the findings of major studies on levosimendan and concludes that levosimendan can significantly improve the clinical symptoms of heart failure in patients. However, this conclusion has not been confirmed in any large randomized controlled trials [77]. The beneficial effects of levosimendan outlined above usually appear within 24 h and include significantly reducing the NT-BNP levels within five posttreatment days, improving the results of cardiac ultrasound and invasive hemodynamics, and improving hemodynamics without increasing myocardial oxygen consumption in patients. These effects can last for approximately one week and are not affected by beta-blockers and other cardiovascular drugs used by patients. Although some recent large randomized controlled trials, i.e., REVIVE, SURVIVE, and LeoPARDS, have produced neutral results, no more adverse outcomes

---

**Table 2:** Details of the use of levosimendan in critical illnesses.

| Acute decompensated heart failure (ADHF) | Is recommended/is indicated |
| ADHF complicating acute myocardial infarction | |
| Acute coronary syndrome. | |
| Septic shock | May be considered |
| Cardiogenic shock | |
| Pulmonary hypertension and right ventricular dysfunction | |
| Heart surgery | Need more research |
| Weaning from ventilator | |
| Sepsis-induced diaphragm dysfunction | |
| Weaning from extracorporeal membrane oxygenation | |
| Cardiorenal syndrome | |
| Liver surgery | |
| Subarachnoid hemorrhage | |

---

**Figure 2:** TSA: the optimal information size of 2082 patients for detection of the plausible treatment effect of levosimendan in sepsis and the Lan–DeMets sequential monitoring boundary constructed by the optimal information size did not cross (reproduced from Chang et al., [65]).
are observed after levosimendan treatment despite those adverse reactions, such as benign arrhythmia and controlled hypotension. Therefore, further randomized controlled trials are necessary to validate the role of levosimendan. For the liver and kidney function of specific populations, these limited studies have suggested a protective effect of levosimendan, but the underlying mechanism remains to be verified. Given the variations of levosimendan effects on the function of diaphragmatic muscles and other respiratory muscles in basic and clinical studies, further studies are needed to identify the specific mechanism and the relationship with blockades of certain cell signaling pathways to reduce the number of pyroptotic diaphragmatic muscle cells.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

J. P and Y.-Q. L were responsible for the literature search and the first draft of this article. J.-Y. Z was responsible for language polishing. Y.-M. Y was responsible for drawing the figure. Y.-Q. L contributed to further editing of the manuscript. All the authors contributed to the preparation of this manuscript and read and approved the final manuscript.

Acknowledgments

This work was supported by grants from the Project of Department of Education of Zhejiang Province (Y201635870).

References

[1] M. M. Givertz, C. Andreou, H. Conrad, and W. S. Colucci, “Direct myocardial effects of levosimendan in humans with left ventricular dysfunction: alteration of force-frequency and relaxation-frequency relationships,” Circulation, vol. 115, no. 10, pp. 1218–1224, 2007.

[2] V. Deschodt-Arsac, G. Calmettes, G. Raffard et al, “Absence of mitochondrial activation during levosimendan inotropic action in perfused paced guinea pig hearts as demonstrated by modular control analysis,” American Journal of Physiology-Regulatory, Integrative and Comparative Physiology, vol. 299, no. 3, pp. R786–R792, 2010.

[3] J. Levijoki, P. Pollesello, J. Kaivola et al., “Further evidence for the cardiac troponin C mediated calcium sensitization by levosimendan: structure-response and binding analysis with analogs of levosimendan,” Journal of Molecular and Cellular Cardiology, vol. 32, no. 3, pp. 479–491, 2000.

[4] I. Ikonomidis, J. T. Parissis, L. Paraskevaidis et al., “Effects of levosimendan on coronary artery flow and cardiac performance in patients with advanced heart failure,” European Journal of Heart Failure, vol. 9, no. 12, pp. 1172–1177, 2007.

[5] A. D. Michaels, B. McKeown, M. Kostal et al., “Effects of intravenous levosimendan on human coronary vasomotor regulation, left ventricular wall stress, and myocardial oxygen uptake,” Circulation, vol. 111, no. 12, pp. 1504–1509, 2005.

[6] M. S. Nieminen, M. Buerke, A. Cohen-Solal et al., “The role of levosimendan in acute heart failure complicating acute coronary syndrome: a review and expert consensus opinion,” International Journal of Cardiology, vol. 218, pp. 150–157, 2016.

[7] H. Yokoshiki, Y. Katsube, M. Sunagawa, and N. Sperelakis, “Levosimendan, a novel Ca2+ sensitizer, activates the glitoclalami-de-sensitive K+ channel in rat arterial myocytes,” European Journal of Pharmacology, vol. 333, no. 2-3, pp. 249–259, 1997.

[8] S. C. Sezen, A. Kitick, A. Özer et al., “Assessment of the effects of levosimendan and thymoquinone on lung injury after myocardial ischemia reperfusion in rats,” Drug Design, Development and Therapy, vol. 12, pp. 1347–1352, 2018.

[9] H. W. H. van Hees, P. N. R. Dekhuijzen, and L. M. A. Heunks, “Levosimendan enhances force generation of diaphragm muscle from patients with chronic obstructive pulmonary disease,” American Journal of Respiratory and Critical Care Medicine, vol. 179, no. 1, pp. 41–47, 2009.

[10] J. Doorduin, C. A. Sinderby, I. Beck et al., “The calcium sensitizer levosimendan improves human diaphragm function,” American Journal of Respiratory and Critical Care Medicine, vol. 185, no. 1, pp. 90–95, 2012.

[11] K. A. Krychtiuk, L. Watzke, C. Kaun et al., “Levosimendan exerts anti-inflammatory effects on cardiac myocytes and endothelial cells in vitro,” Thrombosis and Haemostasis, vol. 113, no. 2, pp. 350–362, 2015.

[12] Q. Wang, H. Yokoo, M. Takashina et al., “Anti-inflammatory profile of levosimendan in cecal ligation-induced septic mice and in lipopolysaccharide-stimulated macrophages,” Critical Care Medicine, vol. 43, no. 11, pp. e508–e520, 2015.

[13] M. Adam, S. Meyer, H. Knors et al., “Levosimendan displays anti-inflammatory effects and decreases MPO bioavailability in patients with severe heart failure,” Scientific Reports, vol. 5, no. 1, p. 9704, 2015.

[14] J. Wang, H. Chen, Y. Zhou, Q. Su, T. Liu, and L. Li, “Levosimendan pretreatment inhibits myocardial apoptosis in swine under coronary microembolization,” Cellular Physiology and Biochemistry, vol. 41, no. 1, pp. 67–78, 2017.

[15] M. Malmberg, T. Vähäisälä, A. Saraste et al., “Intracoronary levosimendan during ischemia prevents myocardial apoptosis,” Frontiers in Physiology, vol. 3, p. 17, 2012.

[16] H. C. Huang, H.-J. Tsai, C.-C. Wang et al., “Levosimendan mitigates coagulopathy and organ dysfunction in rats with endotoxemia,” Journal of the Chinese Medical Association, vol. 80, no. 7, pp. 432–441, 2017.

[17] J. Sikora, K. Pstrągowski, N. Skibińska et al., “Impact of levosimendan on coronary artery flow and cardiac perfusion,” European Journal of Pharmacology, vol. 769, pp. 249–259, 2017.

[18] F. Bent and K. Plaschke, “Levosimendan’s effect on platelet function,” Platelets, vol. 24, no. 3, pp. 189–193, 2013.

[19] M. Gooshe, M. Tabaeizadeh, A. R. Aleyasin et al., “Levosimendan exerts anticonvulsant properties against PTZ-induced seizures in mice through activation of nNOS/NO pathway: role for KATP channel,” Life Sciences, vol. 168, pp. 38–46, 2017.

[20] M. Okada and H. Yamawaki, “Levosimendan inhibits interleukin-1beta-induced apoptosis in rat cardiac fibroblasts,” European Journal of Pharmacology, vol. 769, pp. 86–92, 2015.

[21] F. Follath, J. G. F. Cleland, H. Just et al., “Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial,” Lancet, vol. 360, no. 9328, pp. 196–202, 2002.
[22] V. S. Moiseyev, P. Pöder, N. Andrejevs et al., “Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN),” *European Heart Journal*, vol. 23, no. 18, pp. 1422–1432, 2002.

[23] A. Mebazaa, M. S. Nieminen, M. Packer et al., “Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial,” *JAMA*, vol. 297, no. 17, pp. 1883–1891, 2007.

[24] M. Packer, W. Colucci, L. Fisher et al., “Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure,” *JACC: Heart Failure*, vol. 1, no. 2, pp. 103–111, 2013.

[25] V. P. Harjola, G. Giannakoulas, D. von Lewinski et al., “Use of levosimendan in acute heart failure,” *European Heart Journal Supplements*, vol. 20, no. Suppl I, pp. 12–110, 2018.

[26] Z. Papp, I. Edes, S. Fruhwald et al., “Levosimendan: molecular mechanisms and clinical implications: consensus of experts on the mechanisms of action of levosimendan,” *International Journal of Cardiology*, vol. 159, no. 2, pp. 82–87, 2012.

[27] J.-M. Boles, J. Bion, A. Connors et al., “Weaning from mechanical ventilation,” *European Respiratory Journal*, vol. 29, no. 5, pp. 1033–1056, 2007.

[28] G. D. Perkins, D. Mistry, S. Gates et al., “Effect of protocolized weaning with early extubation to noninvasive ventilation vs invasive weaning on time to liberation from mechanical ventilation among patients with respiratory failure: the breathe randomized clinical trial,” *JAMA*, vol. 320, no. 18, pp. 1881–1888, 2018.

[29] E. C. Goligher, N. D. Ferguson, and L. J. Brochard, “Clinical challenges in mechanical ventilation,” *Lancet*, vol. 387, no. 10030, pp. 1856–1866, 2016.

[30] S. Jaber, B. J. Petrof, B. Jung et al., “Rapidly progressive diaphragmatic weakness and injury during mechanical ventilation in humans,” *American Journal of Respiratory and Critical Care Medicine*, vol. 183, no. 3, pp. 364–371, 2011.

[31] K. Maes, A. Stamiris, D. Thomas et al., “Effects of controlled mechanical ventilation on sepsis-induced diaphragm dysfunction in rats,” *Critical Care Medicine*, vol. 42, no. 12, pp. e772–e782, 2014.

[32] G. S. Supinski and L. A. Callahan, “Double-stranded RNA-dependent protein kinase activation modulates endotoxin-induced diaphragm weakness,” *Journal of Applied Physiology*, vol. 110, no. 1, pp. 199–205, 2011.

[33] J. Shi, Y. Zhao, K. Wang et al., “Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death,” *Nature*, vol. 526, no. 7575, pp. 660–665, 2015.

[34] W. J. Schellekens, H. van Hees, M. Linkels et al., “Levosimendan affects oxidative and inflammatory pathways in the diaphragm of ventilated endotoxemic mice,” *Critical Care*, vol. 19, no. 1, p. 69, 2015.

[35] M. Sterba, A. Banerjee, and Y. Mudaliar, “Prospective observational study of levosimendan and weaning of difficult-to-wean ventilator dependent intensive care patients,” *Critical Care & Resuscitation*, vol. 10, no. 3, pp. 182–186, 2008.

[36] A. C. Gordon, G. D. Perkins, M. Singer et al., “Levosimendan for the prevention of acute organ dysfunction in sepsis,” *New England Journal of Medicine*, vol. 375, no. 17, pp. 1638–1648, 2016.

[37] L. Ouanes-Besbes, L. Ouanes, F. Dachraoui, S. Dimassi, A. Mebazaa, and F. Abroug, “Weaning difficult-to-wean chronic obstructive pulmonary disease patients: a pilot study comparing initial hemodynamic effects of levosimendan and dobutamine,” *Journal of Critical Care*, vol. 26, no. 1, pp. 15–21, 2011.

[38] G. L. Oktar, D. N. Amac, C. Elmas et al., “The histopathological effects of levosimendan on liver injury induced by myocardial ischemia and reperfusion,” *Bratislava Medical Journal*, vol. 116, no. 4, pp. 241–247, 2015.

[39] P. Onody, R. Kiang, A. Fulop et al., “Levosimendan: a cardiovascular drug to prevent liver ischemia-reperfusion injury?” *PLoS One*, vol. 8, no. 9, Article ID e73758, 2013.

[40] E. Grossini, P. Pollesello, K. Bellofatto et al., “Protective effects elicited by levosimendan against liver ischemia/reperfusion injury in anesthetized rats,” *Liver Transplantation*, vol. 20, no. 3, pp. 361–375, 2014.

[41] S. N. Brunner, N. V. Bogert, A. A. Schnitzbauer et al., “Levosimendan protects human hepatocytes from ischemia-reperfusion injury,” *PLoS One*, vol. 12, no. 11, Article ID e0187839, 2017.

[42] F. Fedele, K. Karason, and S. Matskepshivili, “Pharmacological approaches to cardio-renal syndrome: a role for the inodilator levosimendan,” *European Heart Journal Supplements*, vol. 19, no. Suppl C, pp. C22–C28, 2017.

[43] M. B. Yilmaz, E. Grossini, J. C. S. Cardoso et al., “Renal effects of levosimendan: a consensus report,” *Cardiovascular Drugs and Therapy*, vol. 27, no. 6, pp. 581–590, 2013.

[44] S. Bouchez, F. Fedele, F. Giannakoulas et al., “Levosimendan in acute and advanced heart failure: an expert perspective on posology and therapeutic application,” *Cardiovascular Drugs and Therapy*, vol. 32, no. 6, pp. 617–624, 2018.

[45] P. S. Pagel, D. A. Hettrick, and D. C. Wartlitt, “Influence of levosimendan, pimobendan, and milrinone on the regional distribution of cardiac output in anaesthetized dogs,” *British Journal of Pharmacology*, vol. 119, no. 3, pp. 609–615, 1996.

[46] V. Faivre, H. Kaskos, J. Callebert et al., “Cardiac and renal effects of levosimendan, arginine vasopressin, and norepinephrine in lipopolysaccharide-treated rabbits,” *Anesthesiology*, vol. 103, no. 3, pp. 514–521, 2005.

[47] A. Oldner, D. Konrad, E. Weitzberg, A. Rudehill, P. Rossi, and M. Wanecek, “Effects of levosimendan, a novel inotropic calcium-sensitizing drug, in experimental septic shock,” *Critical Care Medicine*, vol. 29, no. 11, pp. 2185–2193, 2001.

[48] Z.-Q. Hou, Z.-X. Sun, C. Y. Su et al., “Effect of levosimendan on estimated glomerular filtration rate in hospitalized patients with decompensated heart failure and renal dysfunction,” *Cardiovascular Therapeutics*, vol. 31, no. 2, pp. 108–114, 2013.

[49] F. Fedele, N. Bruno, B. Brisolini, C. Cairia, A. D’Ambrosi, and M. Mancone, “Levosimendan improves renal function in acute decompensated heart failure: possible underlying mechanisms,” *European Journal of Heart Failure*, vol. 16, no. 3, pp. 281–288, 2014.

[50] G. Bragadottir, B. Redfors, and S. E. Ricksten, “Effects of levosimendan on glomerular filtration rate, renal blood flow, and renal oxygenation after cardiac surgery with cardiopulmonary bypass: a randomized placebo-controlled study,” *Critical Care Medicine*, vol. 41, no. 10, pp. 2328–2335, 2013.

[51] H. I. Eriksson, J. R. Jalonen, L. O. Heikkinen et al., “Levosimendan facilitates weaning from cardiopulmonary bypass in patients undergoing coronary artery bypass grafting with impaired left ventricular function,” *The Annals of Thoracic Surgery*, vol. 87, no. 2, pp. 448–454, 2009.

[52] A. Ristikankare, R. Pöyhä, H. Eriksson, M. Valtonen, K. Leino, and M. Salmenperä, “Effects of levosimendan on renal function in patients undergoing coronary artery surgery,” *Journal of Cardiothoracic and Vascular Anesthesia*, vol. 26, no. 4, pp. 591–595, 2012.
[53] R. A. Zager, A. C. Johnson, S. Lund, S. Y. Hanson, and C. K. Abrass, “Levosimendan protects against experimental endotoxemnic acute renal failure,” *American Journal of Physiology-Renal Physiology*, vol. 290, no. 6, pp. F1453–F1462, 2006.

[54] J. A. Alhashemi, Q. A. Alotaibi, G. M. Abdullah, and S. A. Shalabi, “Levosimendan vs dobutamine in septic shock,” *Journal of Critical Care*, vol. 24, no. 3, pp. e14–e15, 2009.

[55] M. Fang and S. Dong, “Effects of levosimendan on hemodynamics and cardiac function in patients with septic shock,” *Zhonghua Wei Zhong Bing Ji Jiu Yi Xue*, vol. 26, no. 10, pp. 692–696, 2014.

[56] D. Memis, M. T. Inal, and N. Sut, “The effects of levosimendan vs dobutamine added to dopamine on liver functions assessed with noninvasive liver function monitoring in patients with septic shock,” *Journal of Critical Care*, vol. 27, no. 3, pp. 318.e1–e6, 2012.

[57] J. I. Meng, M. H. Hu, Z. Z. Lai et al., “Levosimendan versus dobutamine in myocardial injury patients with septic shock: a randomized controlled trial,” *Medical Science Monitor*, vol. 22, pp. 1486–1496, 2016.

[58] A. Morelli, S. De Castro, J.-L. Teboul et al., “Effects of levosimendan on systemic and regional hemodynamics in septic myocardial depression,” *Intensive Care Medicine*, vol. 31, no. 5, pp. 638–644, 2005.

[59] A. Morelli, A. Donati, C. Ertmer et al., “Levosimendan for resuscitating the microcirculation in patients with septic shock: a randomized controlled study,” *Critical Care*, vol. 14, no. 6, p. R232, 2010.

[60] X. Wang and S. Li, “Effect of small-dose levosimendan on mortality rates and organ functions in Chinese elderly patients with sepsis,” *Clinical Interventions in Aging*, vol. 12, pp. 917–921, 2017.

[61] S. Valli, C. Ferdynus, R. Persichini et al., “Impact of levosimendan on weaning from peripheral venoarterial extracorporeal membrane oxygenation in intensive care unit,” *Annals of Intensive Care*, vol. 9, no. 1, p. 24, 2019.

[62] A. Morelli and L. Tritapepe, “Levosimendan in sepsis,” *New England Journal of Medicine*, vol. 376, no. 8, pp. 798–800, 2017.

[63] A. Zangrillo, A. Putzu, F. Monaco et al., “Levosimendan reduces mortality in patients with severe sepsis and septic shock: a meta-analysis of randomized trials,” *Journal of Critical Care*, vol. 30, no. 5, pp. 908–913, 2015.

[64] S. Bhattacharjee, K. D. Soni, S. Maitra, and D. K. Baidya, “Levosimendan does not provide mortality benefit over dobutamine in adult patients with septic shock: a meta-analysis of randomized controlled trials,” *Journal of Clinical Anesthesia*, vol. 39, pp. 67–72, 2017.

[65] W. Chang, J.-F. Xie, J.-Y. Xu, and Y. Yang, “Effect of levosimendan on mortality in severe sepsis and septic shock: a meta-analysis of randomised trials,” *BMJ Open*, vol. 8, no. 3, Article ID e019338, 2018.

[66] H. Thiele, U. Zeymer, F.-J. Neumann et al., “Intraaortic balloon support for myocardial infarction with cardiogenic shock,” *New England Journal of Medicine*, vol. 367, no. 14, pp. 1287–1296, 2012.

[67] D. Kolte, S. Khera, W. S. Aronow et al., “Trends in incidence, management, and outcomes of cardiogenic shock complicating ST-elevation myocardial infarction in the United States,” *Journal of the American Heart Association*, vol. 3, no. 1, Article ID e000590, 2014.

[68] R. J. Goldberg, F. A. Spencer, J. M. Gore, D. Lessard, and J. Yarzubski, “Thirty-year trends (1975 to 2005) in the magnitude of, management of, and hospital death rates associated with cardiogenic shock in patients with acute myocardial infarction: a population-based perspective,” *Circulation*, vol. 119, no. 9, pp. 1211–1219, 2009.

[69] R. J. Goldberg, R. C. P. Makam, J. Yarzebski, D. D. McManus, D. Lessard, and J. M. Gore, “Decade-long trends (2001–2011) in the incidence and hospital death rates associated with the in-hospital development of cardiogenic shock after acute myocardial infarction,” *Circulation: Cardiovascular Quality and Outcomes*, vol. 9, no. 2, pp. 117–125, 2016.

[70] N. Aissaoui, E. Puymirat, X. Tabone et al., “Improved outcome of cardiogenic shock at the acute stage of myocardial infarction: a report from the USIK 1995, USIC 2000, and FAST-MI French nationwide registries,” *European Heart Journal*, vol. 33, no. 20, pp. 2535–2543, 2012.

[71] M. Fang, H. Cao, and Z. Wang, “Levosimendan in patients with cardiogenic shock complicating myocardial infarction: a meta-analysis,” *Medicina Intensiva (English Edition)*, vol. 42, no. 7, pp. 409–415, 2018.

[72] A. Affronti, I. di Bella, D. Carino, and T. Ragni, “Levosimendan may improve weaning outcomes in venoarterial ECMO patients,” *ASAIO Journal*, vol. 59, no. 6, pp. 554–557, 2013.

[73] S. Busani, A. Pasetto, G. Ligabue, V. Malavasi, R. Lugli, and M. Girardis, “Levosimendan in a case of severe peri-myocarditis associated with influenza A/H1N1 virus,” *British Journal of Anaesthesia*, vol. 109, no. 6, pp. 1011–1013, 2012.

[74] S. Erkan, V. Davutoglu, M. Cakici et al., “Rapid recovery from acute myocarditis under levosimendan treatment: report of two cases,” *Journal of Clinical Pharmacy and Therapeutics*, vol. 38, no. 2, pp. 179–180, 2013.

[75] I. Lábbene, M. Arrigo, M. Tavares et al., “Decongestive effects of levosimendan in cardiogenic shock induced by postpartum cardiomyopathy,” *Anaesthesia Critical Care & Pain Medicine*, vol. 36, no. 1, pp. 39–42, 2017.

[76] J. T. Sieweke, T. Jonathan Pfeffer, D. Berliner et al., “Cardiogenic shock complicating cardiomyopathy: importance of early left ventricular unloading and bromocriptine therapy,” *European Heart Journal: Acute Cardiovascular Care*, vol. 1, pp. 1–10, 2018.

[77] C. Maack, T. Eschenhagen, N. Hamdani et al., “Treatments targeting inotropy,” *European Heart Journal*, pp. 1–19, 2018.